Influence of surgical treatment of obesity on the course of nonalcoholic fatty liver disease
https://doi.org/10.14341/omet12978
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a liver disease with a characteristic accumulation of fatty inclusions in hepatocytes and includes a spectrum of liver lesions from steatosis to cirrhosis. In view of the increasing incidence of obesity and associated NAFLD, a search is underway for optimal treatments. The authors analyzed published clinical studies on the effect of bariatric surgery on morphological changes in the liver. The literature was searched for the keywords «non-alcoholic fatty liver disease», «obesity», «bariatric surgery» in Pubmed databases and еLibrary.ru for the period from 1990 to 2022 . Both the positive effects of surgical treatment of obesity in the form of a decrease in steatosis, steatohepatitis of the liver, and adverse effects in the form of aggravation of cirrhosis in patients after surgery are considered. Despite the obvious effectiveness of bariatric surgery in relation to the components of the metabolic syndrome associated with obesity, there is still no unambiguous opinion about their effectiveness in relation to NAFLD.
About the Authors
A. S. Pushkareva
Endocrinology Research Centre
Russian Federation
Russian Federation
Anastasiya S. Pushkareva, MD
11 Dm. Ulyanova street, 117036 Moscow
eLibrary SPIN: 1996-5308
N. V. Mazurina
Endocrinology Research Centre
Russian Federation
Russian Federation
Natalya V. Mazurina, MD, PhD
Moscow
eLibrary SPIN: 9067-3062
K. A. Komshilova
Endocrinology Research Centre
Russian Federation
Russian Federation
Kseniya A. Komshilova, MD, PhD
Moscow
eLibrary SPIN: 2880-9644
E. V. Ershova
Endocrinology Research Centre
Russian Federation
Russian Federation
Ekaterina V. Ershova, MD, PhD
Moscow
eLibrary SPIN: 6728-3764
References
1. Lazebnik LB, Golovanova EV, Turkina SV, et al. Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version. Experimental and Clinical Gastroenterology. 2021;1(1):4-52. (In Russ.). doi: https://doi.org/10.31146/1682-8658-ecg-185-1-4-52
2. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. doi: https://doi.org/10.1002/hep.28431
3. Ong JP, Younossi ZM. Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis. 2007;11(1):1-16. doi: https://doi.org/10.1016/j.cld.2007.02.009
4. Leite NC, Salles GF, Araujo ALE, et al. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int. 2009;29(1):113-119. doi: https://doi.org/10.1111/j.1478-3231.2008.01718.x
5. Assy N, Kaita K, Mymin D, et al. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci. 2000;45(10):1929-1934. doi: https://doi.org/10.1023/a:1005661516165
6. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005-2023. doi: https://doi.org/10.1002/hep.25762
7. Drapkina OM, Ivashkin VT. Jepidemiologicheskie osobennosti nealkogol’noj zhirovoj bolezni pecheni v Rossii (rezul’taty otkrytogo mnogo centrovogo prospektivnogo issledovanija DIREGL 019030). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2014;24(4):32-38. (In Russ.).
8. Fujioka K. Current and emerging medications for overweight or obesity in people with comorbidities. Diabetes, Obes Metab. 2015;17(11):1021-1032. doi: https://doi.org/10.1111/dom.12502
9. VanWagner LB, Rinella ME. Extrahepatic manifestations of nonalcoholic fatty liver disease. Curr Hepatol Reports. 2016;15(2):75-85. doi: https://doi.org/10.1007/s11901-016-0295-9
10. Sasaki A, Nitta H, Otsuka K, et al. Bariatric surgery and non-alcoholic fatty liver disease: Current and potential future treatments. Front Endocrinol (Lausanne). 2014;5(2):75-85. doi: https://doi.org/10.3389/fendo.2014.00164
11. Subichin M, Clanton J, Makuszewski M, et al. Liver disease in the morbidly obese: a review of 1000 consecutive patients undergoing weight loss surgery. Surg Obes Relat Dis. 2015;11(1):137-141. doi: https://doi.org/10.1016/j.soard.2014.06.015
12. Festi D, Colecchia A, Sacco T, et al. Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes Rev. 2004;5(1):27-42. doi: https://doi.org/10.1111/j.1467-789x.2004.00126.x
13. Petersen KF, Dufour S, Feng J, et al. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc Natl Acad Sci. 2006;103(48):18273-18277. doi: https://doi.org/10.1073/pnas.0608537103
14. Petersen KF, Dufour S, Hariri A, et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med. 2010;362(12):1082-1089. doi: https://doi.org/10.1056/NEJMoa0907295
15. Petta S, Muratore C, Craxì A. Non-alcoholic fatty liver disease pathogenesis: The present and the future. Dig Liver Dis. 2009;41(9):615-625. doi: https://doi.org/10.1016/j.dld.2009.01.004
16. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40(12):1461-1465. doi: https://doi.org/10.1038/ng.257
17. Mishina EE, Mayorov AY, Bogomolov PO, et al. Nonalcoholic fatty liver disease: cause or consequence of insulin resistance? Diabetes mellitus. 2017;20(5):335-343. (In Russ.). doi: https://doi.org/10.14341/DM9372
18. Prashanth M, Ganesh HK, Vima MV, et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. J Assoc Physicians India. 2009;(57):205-210.
19. Fan N, Zhang L, Xia Z, et al. Sex-specific association between serum uric acid and nonalcoholic fatty liver disease in type 2 diabetic patients. J Diabetes Res. 2016;2016:1-6. doi: https://doi.org/10.1155/2016/3805372
20. Kiseleva EV, Demidova TY. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the problem of conjunction and phasing. Obesity and metabolism. 2021;18(3):313-319. (In Russ.). doi: https://doi.org/10.14341/omet12758
21. Drapkina OM, Korneeva ON. Continuum of non-alcoholic fatty liver disease: from hepatic steatosis to cardiovascular risk. Ration Pharmacother Cardiol. 2016;12(4):424-429. (In Russ.). doi: https://doi.org/10.20996/1819-6446-2016-12-4-424-429
22. Wu K-T, Kuo P-L, Su S-B, et al. Nonalcoholic fatty liver disease severity is associated with the ratios of total cholesterol and triglycerides to high-density lipoprotein cholesterol. J Clin Lipidol. 2016;10(2):420-425.e1. doi: https://doi.org/10.1016/j.jacl.2015.12.026
23. Fassio E, Alvarez E, Dominguez N, et al. Natural history of nonalcoholic steatohepatitis: A longitudinal study of repeat liver biopsies. Hepatology. 2004;40(4):820-826. doi: https://doi.org/10.1002/hep.20410
24. Hashimoto E, Yatsuji S, Kaneda H, et al. The characteristics and natural history of Japanese patients with nonalcoholic fatty liver disease. Hepatol Res. 2005;33(2):72-76. doi: https://doi.org/10.1016/j.hepres.2005.09.007
25. Adams LA, Lymp JF, St. Sauver J, et al. The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology. 2005;129(1):113-121. doi: https://doi.org/10.1053/j.gastro.2005.04.014
26. Miyaaki H, Ichikawa T, Nakao K, et al. Clinicopathological study of nonalcoholic fatty liver disease in Japan: the risk factors for fibrosis. Liver Int. 2007;28(4):519-524. doi: https://doi.org/10.1111/j.1478-3231.2007.01614.x
27. Ascha MS, Hanouneh IA, Lopez R, et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51(6):1972-1978. doi: https://doi.org/10.1002/hep.23527
28. Hashimoto E, Yatsuji S, Tobari M, et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol. 2009;44(S19):89-95. doi: https://doi.org/10.1007/s00535-008-2262-x
29. Misra VL, Khashab M, Chalasani N. Nonalcoholic fatty liver disease and cardiovascular risk. Curr Gastroenterol Rep. 2009;11(1):50-55. doi: https://doi.org/10.1007/s11894-009-0008-4
30. Stefan N, Kantartzis K, Häring H-U. Causes and metabolic consequences of fatty liver. Endocr Rev. 2008;29(7):939-960. doi: https://doi.org/10.1210/er.2008-0009
31. Shirokova EN. Non-alcoholic fatty liver disease, hyperlipidemia and cardiovascular risks. Consilium Medicum. 2017;19(8.2. Gastroenterology):74-76. (In Russ.). doi: https://doi.org/10.26442/2075-1753_19.8.2.74-76
32. Haufe S, Engeli S, Kast P, et al. Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects. Hepatology. 2011;53(5):1504-1514. doi: https://doi.org/10.1002/hep.24242
33. Asrih M, Jornayvaz FR. Diets and nonalcoholic fatty liver disease: The good and the bad. Clin Nutr. 2014;33(2):186-190. doi: https://doi.org/10.1016/j.clnu.2013.11.003
34. Asrih M, Jornayvaz FR. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388-1402. doi: https://doi.org/10.1016/j.jhep.2015.11.004
35. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357. doi: https://doi.org/10.1002/hep.29367
36. Houmard JA, Tanner CJ, Slentz CA, et al. Effect of the volume and intensity of exercise training on insulin sensitivity. J Appl Physiol. 2004;96(1):101-106. doi: https://doi.org/10.1152/japplphysiol.00707.2003
37. Kopp C, Kopp H-P, Steiner S, et al. Weight loss reduces tissue factor in morbidly obese patients. Obes Res. 2003;11(8):950-956. doi: https://doi.org/10.1038/oby.2003.131
38. Lyzlova SM, Fishman MB, Rajhel’son KL. Potencial’noe vlijanie bariatricheskih operacij na techenie nealkogol’noj bolezni pecheni u pacientov s morbidnym ozhireniem. Evrazijskij sojuz uchenyh. Medicinskie nauki. 2015;3(12):91-93. (In Russ.). doi : https://doi.org/10.31618/ESU.2413-9335
39. Buchwald H., Avidor Y., Braunwald E. et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292(14):1724. doi: https://doi.org/10.1001/jama.292.14.1724
40. Kornjushin OV, Toropova JaG, Nejmark AE, et al. Mehanizmy vlijanija bariatricheskih operacij na techenie nealkogol’noj zhirovoj bolezni pecheni. Experimental and Clinical Gastroenterology. 2017;146(10):61-73. (In Russ.).
41. Ranløv I, Hardt F. Regression of liver steatosis following gastroplasty or gastric bypass for morbid obesity. Digestion. 1990;47(4):208-214. doi: https://doi.org/10.1159/000200499
42. Craig CM, Liu L-F, Deacon CF, et al. Critical role for GLP-1 in symptomatic post-bariatric hypoglycaemia. Diabetologia. 2017;60(3):531-540. doi: https://doi.org/10.1007/s00125-016-4179-x
43. Steinert RE, Feinle-Bisset C, Asarian L, et al. Ghrelin, CCK, GLP-1, and PYY(3–36): secretory controls and physiological roles in eating and glycemia in health, obesity, and after RYGB. Physiol Rev. 2017;97(1):411-463. doi: https://doi.org/10.1152/physrev.00031.2014
44. Costa Justus JF, Ligocki Campos AC, Figueroa ALC, et al. Early effect of bariatric surgery on the circadian rhythms of adipokines in morbidly obese women. Metab Syndr Relat Disord. 2016;14(1):16-22. doi: https://doi.org/10.1089/met.2015.0051
45. Kornyushin OV, Toropova YG, Berko OM, et al. Morphological changes in the liver in rats for liver diseases and decompensated type 2 diabetes after performing various types of bariatric operations. Experimental and Clinical Gastroenterology. 2019;(8):72-76. (In Russ.). doi: https://doi.org/10.31146/1682-8658-ecg-168-8-72-76
46. Froylich D, Corcelles R, Daigle C, et al. Effect of Roux-en-Y gastric bypass and sleeve gastrectomy on nonalcoholic fatty liver disease: a comparative study. Surg Obes Relat Dis. 2016;12(1):127-131. doi: https://doi.org/10.1016/j.soard.2015.04.004
47. Aguilar-Olivos NE, Almeda-Valdes P, Aguilar-Salinas CA. et al. The role of bariatric surgery in the management of nonalcoholic fatty liver disease and metabolic syndrome. Metabolism. 2016;65(8):1196-1207. doi: https://doi.org/10.1016/j.metabol.2015.09.004
48. Taitano AA, Markow M, Finan JE, et al. Bariatric surgery improves histological features of nonalcoholic fatty liver disease and liver fibrosis. J Gastrointest Surg. 2015;19(3):429-437. doi: https://doi.org/10.1007/s11605-014-2678-y
49. Aldoheyan T, Hassanain M, Al-Mulhim A, et al. The effects of bariatric surgeries on nonalcoholic fatty liver disease. Surg Endosc. 2017;31(3):1142-1147 doi: https://doi.org/10.1007/s00464-016-5082-8
50. Major P, Pędziwiatr M, Rubinkiewicz M, et al. Impact of bariatric surgery on non-alcoholic fatty liver disease. Pol Przegl Chir. 2017;89(2):1-4 doi: https://doi.org/10.5604/01.3001.0009.6003
51. Nickel F, Tapking C, Benner L, et al. Bariatric surgery as an efficient treatment for non-alcoholic fatty liver disease in a prospective study with 1-year follow-up. Obes Surg. 2018;28(5):1342-1350. doi: https://doi.org/10.1007/s11695-017-3012-z
52. Chaim FDM, Pascoal LB, Chaim FHM, et al. Histological grading evaluation of non-alcoholic fatty liver disease after bariatric surgery: a retrospective and longitudinal observational cohort study. Sci Rep. 2020;10(1):8496. doi: https://doi.org/10.1038/s41598-020-65556-2
53. Mummadi RR, Kasturi KS, Chennareddygari S, Sood GK. Effect of bariatric surgery on nonalcoholic fatty liver disease: Systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2008;6(12):1396-1402. doi: https://doi.org/10.1016/j.cgh.2008.08.012
54. Silverman EM, Sapala JA, Appelman HD. Regression of hepatic steatosis in morbidly obese persons aft er gastric bypass. Am J Clin Pathol. 1995;104(1):23-31. doi: https://doi.org/10.1093/ajcp/104.1.23
55. Kral JG, Thung SN, Biron S, et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery. 2004;135(1):48-58. doi: https://doi.org/10.1016/j.surg.2003.10.003
56. Csendes A, Smok G, Burgos AM. Histological findings in the liver before and after gastric bypass. Obes Surg. 2006;16(5):607-611. doi: https://doi.org/10.1381/096089206776944904
57. Mathurin P, Hollebecque A, Arnalsteen L, et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology. 2009;137(2):532-540. doi: https://doi.org/10.1053/j.gastro.2009.04.052
58. Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, et al. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev. 2010;6(12):1396-1402. doi: https://doi.org/10.1002/14651858.CD007340.pub2
Supplementary files
|
|
1. Figure 1. Histologic appearance of the liver (adapted from Chaim, F.D.M. and coauthors, 2020) [52]). | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(1MB)
|
Indexing metadata ▾ | |
Review
For citations:
Pushkareva A.S., Mazurina N.V., Komshilova K.A., Ershova E.V. Influence of surgical treatment of obesity on the course of nonalcoholic fatty liver disease. Obesity and metabolism. 2023;20(3):237-244. (In Russ.) https://doi.org/10.14341/omet12978
Views:
1607
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
